Our research demonstrated for the first time that Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in lung cancer cells, and suggested promise as a marker for patients likely to benefit from cisplatin-based chemotherapy. The gene discussed is MAPK8; the disease is lung carcinoma.